The stats say when an old NFL team wins the super bowl, the market will go up. Old AFL team wins, market goes down. It's been right 82% of time for the 49 Super Bowls. Lets hope it's a contrary indicator again this year for for AMRN. With Denver , it says market will be down this year, Market was down last year with Pats win, but AMRN up for the year (yes, believe it or not)
It would be nice if management put out some PR in the next day that RI is now fully enrolled, since they've stated several times they expected it to be fully enrolled by year end. At least give shareholders a deserved nice warm comfy feeling for New Years, and certainly supportive of their arguments against FDA. Too much to ask?
CHMA must have some respect for Thero as he's in good company. They also named Tobin, former ceo of Biogen and Boston Scientific.
There are a lot of options out there to lessen cancer risk, as well. Like not smoking. Additionally, now, FDA is cracking down on these ultra high priced stocks that may have very slight benefit with high risks / side affects. We know all cancer treatments, regrettably, have minimum benefit and high side effects, costs. I wish it weren't so. I wish there were a Vascepa for cancer....I say that.for the sake of cancer patients, not from an investor perspective.
CLVS has no drugs on the market. Little prospect of any drugs on the market any time soon,
reported a $98 million (yes million) loss last quarter (yes quarter) and yet was commanding a $100 pps last week. At $30 pps today/ It should be at .03 cents. I bring this up only to reinforce my original post of the huge disconnect in biotech stocks. Recognizing the risks (slight) with AMRN, it is a screaming buy at this point in time at this pps.
Yes, compare balance sheets of CLVS and AMRN. Still argue that CLVS desired at $100 pps last week, let alone $30 today? AMRN looks stellar by compariosn
Heart disease #1 cause of death in US, ahead of all cancers. Vascepa a low cost, effective and safe way to mitigate heart disease CLVS drug limited specifically at lung cancer, of which there were about 158k deaths. CLVS not yet proven effective or safe and anticipated high cost. Why the $100 pps last week.
In't there a disconnect here? We see CLVS taking a 70% pps cut today (from about $100 to $30) because FDA asked for more data o their cancer drug. CLVS had no approved drugs, only Phase 2 trial and yet had been selling around $100 for awhile. Even if they got past Phase 3 trails, revenue still a along way off. AMRN has an approved drug, generating revenue with likely potential for a 10x expansion over the next few / several months (short time for biotechs) and yet can trade more than a couple of bucks. Stock has essentially been de-risked
and has very significant potential.